Lumira Capital Leads $13.25M Financing of enGene
Canadian venture capital firm Lumira Capital has led a $13.25 million financing of enGene Inc., a biopharmaceuticals company focused on nucleotide-based therapeutics. The investment was undertaken via Lumira's Merck Lumira Biosciences Fund. As a result, enGene will relocate its headquarters to Montréal, where it will leverage local infrastructure, build operations and execute its business plan. Lumira in 2012 closed Lumira Capital II and the Merck fund, a partnership with Merck Canada.
6 August 2013•3 mins read
